AXL receptor tyrosine kinase as a therapeutic target in NSCLC
Ross A Okimoto,1 Trever G Bivona1,2 1Division of Hematology and Medical Oncology, University of California San Francisco, San Francisco, CA, USA; 2Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA Abstract: The AXL receptor tyrosine kina...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/66beb47003984936bec97fbf70841834 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Ross A Okimoto,1 Trever G Bivona1,2 1Division of Hematology and Medical Oncology, University of California San Francisco, San Francisco, CA, USA; 2Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA Abstract: The AXL receptor tyrosine kinase and its ligand, Gas6, regulate key processes in lung cancer growth, metastasis, and epithelial–mesenchymal transition-associated drug resistance. Gas6 and AXL expression have been correlated with poor prognosis and advanced clinical stage in patients with lung cancer, and targeting the Gas6/AXL pathway demonstrates antitumor activity, decreases cellular invasion, and restores sensitivity in de novo and acquired drug resistance models. These findings implicate AXL as a promising therapeutic target in lung cancer. In this review, we explore the role of AXL in lung cancer progression, from tumor development to disseminated disease, and highlight the current clinical landscape of anti-AXL therapeutics. Keywords: Gas6, lung cancer, targeted therapy, drug resistance |
|---|